May Han, MD
Neurology · Stanford, CANPI 1285960005
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $24,875 of the $29,099 with a category attached, or 85.5%. Genentech USA, Inc. accounts for 63.3% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $11,056 and has fallen 56.2% since, to $4,842 in 2024.
Across 26 payments — averaging $1119.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$18K
- Amgen$5K
- Genentech, Inc.$4K
- AstraZeneca$2K
- AbbVie$121
Across 18 payments — averaging $5954.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$61K
- Hoffmann-la Roche Limited$41K
- Novartis$6K
What the payments were for
- Consulting fees$24,87585%
- Travel & lodging$3,32711%
- Food & beverage$8973%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 15 | $18,420 |
| Amgen | 5 | $4,842 |
| Genentech, Inc. | 4 | $3,676 |
| AstraZeneca | 1 | $2,040 |
| AbbVie | 1 | $121 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Non-Covered Product$10,802
- Enspryng$6,090
- OCREVUS$4,995
- UPLIZNA$4,817
- ULTOMIRIS$2,040
How this compares
$29,099 in reported general payments places this provider in the 85th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 31 | $262,253 |
| MayzentSiponimod | 23 | $212,428 |
| Carbamazepine ErCarbamazepine | 14 | $2,063 |
| Baclofen | 77 | $1,576 |
| Teriflunomide | 16 | $950 |
| Duloxetine Hcl | 29 | $806 |
| Modafinil | 13 | $394 |
| Gabapentin | 40 | $393 |
Paid to pharmacies, not to this prescriber.
Other neurology in Stanford
- Jeffrey DunnStanford$437K
- Neelam GoyalStanford$270K
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
- Regina BerkovichWest Hollywood$3M
- Daniel BandariNewport Beach$2.6M
- Perry ShiehLos Angeles$2.4M
- Sandeep ThakkarIrvine$2M
- David LiebeskindLos Angeles$1.9M
- Jack SchimCarlsbad$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.